|
1
|
Crawford SE, Stellmach V, Murphy-Ullrich
JE, et al: Thrombospondin-1 is a major activator of TGF-beta1 in
vivo. Cell. 93:1159–1170. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Presser LD, Haskett A and Waris G:
Hepatitis C virus-induced furin and thrombospondin-1 activate
TGF-β1: role of TGF-β1 in HCV replication. Virology. 412:284–296.
2011.PubMed/NCBI
|
|
3
|
Recouvreux MV, Camilletti MA, Rifkin DB,
Becu-Villalobos D and Diaz-Torga G: Thrombospondin-1 (TSP-1)
analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover
active pituitary transforming growth factor-β1 (TGF-β1).
Endocrinology. 153:3861–3871. 2012.PubMed/NCBI
|
|
4
|
Hayashi H, Sakai K, Baba H and Sakai T:
Thrombospondin-1 is a novel negative regulator of liver
regeneration after partial hepatectomy through transforming growth
factor-beta1 activation in mice. Hepatology. 55:1562–1573. 2012.
View Article : Google Scholar
|
|
5
|
Nakao T, Kurita N, Komatsu M, et al:
Expression of thrombospondin-1 and Ski are prognostic factors in
advanced gastric cancer. Int J Clin Oncol. 16:145–152. 2011.
View Article : Google Scholar
|
|
6
|
Punekar S, Zak S, Kalter VG, et al:
Thrombospondin 1 and its mimetic peptide ABT-510 decrease
angiogenesis and inflammation in a murine model of inflammatory
bowel disease. Pathobiology. 75:9–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reka AK, Kurapati H, Narala VR, et al:
Peroxisome proliferator-activated receptor-gamma activation
inhibits tumor metastasis by antagonizing Smad3-mediated
epithelial-mesenchymal transition. Mol Cancer Ther. 9:3221–3232.
2010. View Article : Google Scholar
|
|
8
|
Dong YW, Wang XP and Wu K: Suppression of
pancreatic carcinoma growth by activating peroxisome
proliferator-activated receptor gamma involves angiogenesis
inhibition. World J Gastroenterol. 15:441–448. 2009. View Article : Google Scholar
|
|
9
|
Shigeto T, Yokoyama Y, Xin B and Mizunuma
H: Peroxisome proliferator-activated receptor alpha and gamma
ligands inhibit the growth of human ovarian cancer. Oncol Rep.
18:833–840. 2007.
|
|
10
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar
|
|
11
|
Wang-Rodriguez J, Urquidi V, Rivard A and
Goodison S: Elevated osteopontin and thrombospondin expression
identifies malignant human breast carcinoma but is not indicative
of metastatic status. Breast Cancer Res. 5:R136–R143. 2003.
View Article : Google Scholar
|
|
12
|
Aspiotis M, Tsanou E, Gorezis S, et al:
Angiogenesis in pterygium: study of microvessel density, vascular
endothelial growth factor, and thrombospondin-1. Eye (Lond).
21:1095–1101. 2007. View Article : Google Scholar
|
|
13
|
Karavasilis V, Malamou-Mitsi V, Briasoulis
E, Tsanou E, Kitsou E and Pavlidis N: Clinicopathologic study of
vascular endothelial growth factor, thrombospondin-1, and
microvessel density assessed by CD34 in patients with stage III
ovarian carcinoma. Int J Gynecol Cancer. 16(Suppl 1): 241–246.
2006. View Article : Google Scholar
|
|
14
|
Baltaci S, Orhan D, Göğüs C, Filiz E,
Tulunay O and Göğüs O: Thrombospondin-1, vascular endothelial
growth factor expression and microvessel density in renal cell
carcinoma and their relationship with multifocality. Eur Urol.
44:76–81. 2003. View Article : Google Scholar
|
|
15
|
Hyder SM, Liang Y and Wu J: Estrogen
regulation of thrombospondin-1 in human breast cancer cells. Int J
Cancer. 125:1045–1053. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fitchev PP, Wcislak SM, Lee C, et al:
Thrombospondin-1 regulates the normal prostate in vivo through
angiogenesis and TGF-beta activation. Lab Invest. 90:1078–1090.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Byrne GJ, Hayden KE, McDowell G, et al:
Angiogenic characteristics of circulating and tumoural
thrombospondin-1 in breast cancer. Int J Oncol. 31:1127–1132.
2007.
|
|
18
|
Elpek GO, Gokhan GA and Bozova S:
Thrombospondin-1 expression correlates with angiogenesis in
experimental cirrhosis. World J Gastroenterol. 14:2213–2217. 2008.
View Article : Google Scholar
|
|
19
|
Jiang M, Mou CZ, Han T, Wang M and Yang W:
Thrombospondin-1 and transforming growth factor-β1 levels in
prolactinoma and their clinical significance. J Int Med Res.
40:1284–1294. 2012.
|
|
20
|
Fontana A, Filleur S, Guglielmi J, et al:
Human breast tumors override the antiangiogenic effect of stromal
thrombospondin-1 in vivo. Int J Cancer. 116:686–691. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kaygusuz G, Tulunay O, Baltaci S and Gogus
O: Microvessel density and regulators of angiogenesis in malignant
and nonmalignant prostate tissue. Int Urol Nephrol. 39:841–850.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pardali K and Moustakas A: Actions of
TGF-beta as tumor suppressor and pro-metastatic factor in human
cancer. Biochim Biophys Acta. 1775:21–62. 2007.PubMed/NCBI
|
|
23
|
Karavasilis V, Malamou-Mitsi V, Briasoulis
E, et al: Angiogenesis in cancer of unknown primary:
clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer.
5:252005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kasper HU, Ebert M, Malfertheiner P,
Roessner A, Kirkpatrick CJ and Wolf HK: Expression of
thrombospondin-1 in pancreatic carcinoma: correlation with
microvessel density. Virchows Arch. 438:116–120. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Y, Wen X, Spataro BC, Hu K, Dai C and
Liu Y: Hepatocyte growth factor is a downstream effector that
mediates the antifibrotic action of peroxisome
proliferator-activated receptor-gamma agonists. J Am Soc Nephrol.
17:54–65. 2006. View Article : Google Scholar
|
|
26
|
Boyer JF, Balard P, Authier H, et al:
Tumor necrosis factor alpha and adalimumab differentially regulate
CD36 expression in human monocytes. Arthritis Res Ther. 9:R222007.
View Article : Google Scholar : PubMed/NCBI
|
